Sino-US healthcare investment specialist Vivo Capital has scored more than $740m for the third cycle of its evergreen Opportunity Fund, which targets small and mid-cap biotech and life science companies.
The post Vivo Capital looks to capture value from medical breakthroughs with $740m boost to evergreen fund appeared first on AltAssets Private Equity News.
